A
Arvinas, Inc. (ARVN)
NMS – Real vaqt narxi. Valyuta: USD
9.57
-0.09 (-0.93%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
9.57
-0.09 (-0.93%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Arvinas, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, kasalliklarga sabab bo'ladigan oqsillarni parchalash uchun terapevtik vositalarni kashf qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya proteolizni maqsad qilib olingan kimyeralarni (PROTAC) ishlab chiqadi, ular kasalliklarga sabab bo'ladigan oqsillarni parchalash va yo'q qilish uchun organizmning tabiiy oqsilni utilizatsiya qilish tizimidan foydalanishga mo'ljallangan. Shuningdek, u klinik rivojlanish dasturlarini ishlab chiqmoqda, jumladan, Parkinson kasalligi va progressiv supranuklear falaj kabi neyrodegenerativ kasalliklarni davolash uchun leysin-takroriy kinaza 2 (LRRK2) oqsili ARV-102; G12D mutatsiyasiga ega bo'lgan oshqozon osti bezi, kolorektal va kichik hujayrali bo'lmagan o'pka saratonini o'z ichiga olgan saratonlarni davolash uchun Kirsten kalamush sarkomasi, G12D oqsili ARV-806; takrorlangan/refrakter bo'lmagan Xochkin limfomasini (NHL) davolash uchun B-hujayrali limfoma 6 oqsili ARV-393; skelet mushaklarida poliglutamin kengaygan androgen retseptori ARV-027; va mahalliy rivojlangan yoki metastatik ER+/HER2- ko'krak bezi saratonini davolash uchun estrogen retseptori vepdegestrant. Bundan tashqari, kompaniya Bavdegalutamide (ARV-110) va Luxdegalutamide (ARV-766) ni ishlab chiqmoqda, ular metastatik kastratsiyaga chidamli prostata saratoniga chalingan erkaklarni davolash uchun tadqiq qilinayotgan og'iz orqali yuboriladigan PROTAC oqsil parchalagichlardir. U Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited va Bayer AG bilan hamkorlik qiladi. Kompaniya 2013 yilda tashkil etilgan va Nyu-Xeyven, Konnektikut shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Noah Berkowitz M.D., Ph.D. | Chief Medical Officer |
| Dr. Randy Teel Ph.D. | CEO, President & Director |
| Mr. Alexander A. Santini | Chief Commercial Officer |
| Mr. Andrew R. Saik | CFO & Treasurer |
| Mr. David K. Loomis M.B.A. | VP & Chief Accounting Officer |
| Mr. Jared M. Freedberg J.D. | General Counsel & Corporate Secretary |
| Mr. Jeff Boyle | Vice President of Investor Relations |
| Mr. Paul McInulty | Senior Vice President of Regulatory Affairs |
| Mr. Steve Weiss | Senior VP & Chief Human Resources Officer |
| Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-01 | 8-K | arvn-20260501.htm |
| 2026-04-29 | DEFA14A | defa14a-coverx2026.htm |
| 2026-04-29 | DEF 14A | arvn-20260429.htm |
| 2026-04-29 | ARS | a2025ars.pdf |
| 2026-03-18 | 8-K | arvn-20260318.htm |
| 2026-02-24 | 8-K | arvn-20260224.htm |
| 2026-02-24 | 10-K | arvn-20251231.htm |
| 2026-02-12 | 8-K | arvn-20260210.htm |
| 2025-12-08 | 8-K | arvn-20251206.htm |
| 2025-11-05 | 10-Q | arvn-20250930.htm |